Liofilchem® Clavulanic acid CLA, Antimicrobial Susceptibility Discs

Liofilchem® Clavulanic Acid (CLA) Antimicrobial Susceptibility Discs are specialized diagnostic tools designed for in vitro antimicrobial susceptibility testing (AST) using the Kirby-Bauer disk diffusion method. Each disc is impregnated with a defined concentration of Clavulanic acid (available in 1 µg, 2 µg, 5 µg, or 10 µg), a potent β-lactamase inhibitor used to assess resistance mechanisms in Gram-negative and Gram-positive bacteria. These discs are manufactured under ISO 9001 and ISO 13485 certified quality management systems to ensure precision, reliability, and reproducibility in laboratory testing.

Key Features

• Multiple Potency Options: Available in 1 µg, 2 µg, 5 µg, and 10 µg disc strengths to support various experimental designs and resistance detection thresholds.
• High-quality β-lactamase inhibitor: Clavulanic acid irreversibly binds to β-lactamases, restoring the activity of companion β-lactam antibiotics.
• CLSI/EUCAST compatible: Suitable for use alongside other β-lactam agents such as amoxicillin, ticarcillin, and cefotaxime to detect synergy or resistance.
• Sterile and stable: Supplied in foil-sealed cartridges or canisters with desiccant to preserve integrity and shelf-life.
• Color-coded and labeled: Easy visual identification of drug concentration and compound.

Applications and Use Cases

1. Clinical Microbiology

• Phenotypic detection of ESBL (Extended-Spectrum Beta-Lactamase) and AmpC β-lactamase production in Enterobacterales.
• Used in synergy testing with third-generation cephalosporins (e.g., cefotaxime + CLA) or penicillins (e.g., amoxicillin + CLA) to detect:
  • ESBL-producing Escherichia coli, Klebsiella pneumoniae
  • AmpC-inducible Enterobacter spp., Citrobacter freundii
• Evaluate restored susceptibility in combination therapies involving clavulanate.

2. Research and Development

• Study concentration-dependent synergy effects in β-lactam/β-lactamase inhibitor combinations.
• Investigate resistance mechanisms in emerging MDR Gram-negative organisms.
• Evaluate the efficacy of novel β-lactamase inhibitor candidates compared to clavulanic acid.

3. Pharmaceutical and QC Testing

• Support the quality control of β-lactam/clavulanate formulations.
• Perform comparative activity testing for development of generics or novel fixed-dose combinations.

Use Instructions

1. Prepare Mueller-Hinton agar plates according to standard protocols.
2. Standardize the bacterial inoculum to 0.5 McFarland turbidity.
3. Inoculate the agar uniformly using a sterile swab.
4. Apply the desired concentration of Clavulanic

Liofilchem® Clavulanic Acid CLA Discs are essential tools for detecting β-lactamase-mediated resistance and evaluating the efficacy of β-lactam/β-lactamase inhibitor combinations in both clinical and research settings. Available in a range of concentrations (1 µg, 2 µg, 5 µg, 10 µg), these discs offer flexibility for phenotypic confirmation of ESBL and AmpC production, synergy testing, and resistance surveillance. Manufactured to meet international quality and performance standards, Liofilchem® CLA discs ensure dependable results for diagnostic laboratories, pharmaceutical quality control, and antimicrobial research programs focused on combating the global threat of antibiotic resistance.